title: miR-455 inhibits breast cancer cell proliferation through targeting CDK14.
abstract: Breast cancer is the most frequently occurring cancer in women worldwide, microRNAs (miRNAs) play critical role in the initiation and progression of breast cancer. Here, we studied the effect of miR-455 on cell proliferation of breast cancer, and found that miR-455 was downregulated in breast cancer tissues and cells. Its overexpression inhibited cell proliferation, whereas its knockdown promoted cell proliferation of breast cancer. We found a Cdc2-related protein kinase CDK14 was the target of miR-455, when the 3'UTR of CDK14 was cloned into luciferase reporter vector and transfected into cells, miR-455 mimic could inhibit the luciferase activity in a dose-dependent manner, miR-455 inhibitor increased the luciferase activity, but the mutant miR-455 mimic couldn't change the luciferase activity, suggesting miR-455 directly bound to the 3'UTR of CDK14. Meanwhile, we also found miR-455 inhibited Cyclin D1 expression and promoted p21 expression, confirming miR-455 inhibited cell proliferation. Double knockdown of miR-455 and CDK14 inhibited the proliferation of breast cancer cell, confirming miR-455 inhibiting cell proliferation by targeting CDK14. Moreover, miR-455 levels were negatively correlated with CDK14 levels in breast cancer tissues. Our finding revealed miR-455 inhibits breast cancer cell proliferation through targeting CDK14, it might be a target for breast cancer therapy.
authors.affiliation: General surgery, Fuzhou General Hospital of Nanjing Military Command, Fuzhou 350025, Fujian, China.
authors.forename: Bing
authors.initials: B
authors.lastname: Wang
authors.affiliation: Oncology Department of the First People's Hospital of Shunde, FoShan 528300, Guangdong, China.
authors.forename: Aimei
authors.initials: A
authors.lastname: Zou
authors.affiliation: Institute of laboratory medicine, Fuzhou General Hospital of Nanjing Military Command, Fuzhou 350025, Fujian, China.
authors.forename: Liqiang
authors.initials: L
authors.lastname: Ma
authors.affiliation: Department of Medical Oncology, Fuzhou General Hospital of Nanjing Military Command, Fuzhou 350025, Fujian, China.
authors.forename: Xiong
authors.initials: X
authors.lastname: Chen
authors.affiliation: General surgery, Fuzhou General Hospital of Nanjing Military Command, Fuzhou 350025, Fujian, China.
authors.forename: Lie
authors.initials: L
authors.lastname: Wang
authors.affiliation: Burn and Plastic surgery, Fuzhou General Hospital of Nanjing Military Command, Fuzhou 350025, Fujian, China.
authors.forename: Ximing
authors.initials: X
authors.lastname: Zeng
authors.affiliation: Burn and Plastic surgery, Fuzhou General Hospital of Nanjing Military Command, Fuzhou 350025, Fujian, China. Electronic address: tiantaiat@sina.com.
authors.forename: Ting
authors.initials: T
authors.lastname: Tan
mesh_terms: D020413:3' Untranslated Regions / Q000235:genetics; D001943:Breast Neoplasms / Q000473:pathology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000235:genetics; D018844:Cyclin-Dependent Kinases / Q000235:genetics*; D015536:Down-Regulation / Q000235:genetics; D006801:Humans; D035683:MicroRNAs / Q000235:genetics*
chemical_list: D020413:3' Untranslated Regions; C583404:MIRN455 microRNA, human; D035683:MicroRNAs; C515076:CDK14 protein, human; D018844:Cyclin-Dependent Kinases
keywords: Breast cancer; CDK14; Cell proliferation; MiR-455